Mucoadhesive buccal tablet of leuprolide and its fatty acid conjugate : Design, in vitro evaluation and formulation strategies

Copyright © 2023 Elsevier B.V. All rights reserved..

This study aimed to design mucoadhesive buccal tablets of leuprolide (LEU) and to manufacture and evaluate the properties of buccal tablets containing LEU-oleic acid conjugate (LOC) and self-assembled LEU-oleic acid nanoparticles (LON), which were developed in a previous study. Hydroxypropyl methylcellulose (HPMC 4000) was used as the mucoadhesive polymer, and tablets were prepared by direct compression. The formulations were characterized by weight, content uniformity, thickness, hardness, swelling index, disintegration time, mucoadhesion time, and drug release. The chosen formulation maintained an adhesion time of up to 6.43 h and a disintegration time of 4.10 h. Drug stability in the mucoadhesive tablets was confirmed after 2 h of storage in human mimic saliva (Phosphate buffer solution pH 6.8). Furthermore, the designed LEU formulation and the LOC and LON developed in a previous study were prepared as buccal tablets and compared. In the dissolution and permeation studies, LON-loaded buccal tablets showed the highest permeation rate. This study suggests that mucoadhesive buccal tablets containing self-assembled LON may effectively increase the medication adherence for pediatric and geriatric patients by improving the bioavailability and permeation rate of LEU.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:639

Enthalten in:

International journal of pharmaceutics - 639(2023) vom: 25. Mai, Seite 122963

Sprache:

Englisch

Beteiligte Personen:

Jin, Hyomin [VerfasserIn]
Ngo, Hai V [VerfasserIn]
Park, Chulhun [VerfasserIn]
Lee, Beom-Jin [VerfasserIn]

Links:

Volltext

Themen:

2UMI9U37CP
Dissolution
EFY6W0M8TG
Fattigation-platform
Fatty Acids
Formulation design
Journal Article
Leuprolide
Leuprolide-oleic acid conjugate
Mucoadhesive buccal tablets
Oleic Acid
Permeation enhancer
Self-assembled nanoparticle
Tablets

Anmerkungen:

Date Completed 12.05.2023

Date Revised 12.05.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.ijpharm.2023.122963

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM355727242